文献速递帕金森病与运动障碍

GBA基因型与新诊断帕金森病患者运动及功能衰退的关联

Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease.
PubMed 文献 · Neurology · 2020-12-21

基于三项欧洲人群研究,随访528例新诊断帕金森病患者,其中440例有基线基因组DNA并评估GBA变异。结果显示GBA携带者UPDRS日常生活活动(ADL)和运动评分年增长更快,且仅招募GBA携带者可缩小临床试验规模达65%。

要点

  • GBA携带者确诊时运动特征与非携带者临床无法区分。
  • GBA携带者ADL和运动评分年增长显著快于非携带者。
  • 仅招募GBA携带者可使临床试验规模缩小最多65%。

核心结论

  • GBA变异与帕金森病患者从诊断起7年内更快的运动疾病进程相关。

研究设计与样本

  • 三项欧洲人群-based研究随访528例新诊断帕金森病患者,其中440例有基线基因组DNA并评估GBA变异。
  • 纳入分析387例特发性患者(基线年龄70.3±9.5岁,男性60.2%)和53例GBA携带者(基线年龄66.8±10.1岁,男性64.2%)。
  • 每年使用UPDRS运动和第日常生活活动(ADL)部分评估运动与功能损害,采用混合随机和固定效应模型评估GBA变异类别的差异效应。

主要发现

  • GBA携带者UPDRS ADL评分年增长1.5分(95% CI 1.1-2.0),非携带者年增长1.0分(95% CI 0.9-1.1),p=0.003。
  • GBA携带者UPDRS运动评分年增长2.2分(95% CI 1.3-3.1),非携带者年增长1.3分(95% CI 1.1-1.6),p=0.007。
  • 临床试验设计模拟显示,仅招募GBA携带者相比招募所有帕金森病患者可使试验规模缩小最多65%。

临床怎么用

  • 对GBA携带者帕金森病患者应关注更快的运动及功能衰退,加强监测与管理。
  • 临床试验设计可考虑富集GBA携带者以提高效率、缩小样本量。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To establish the significance of glucocerebrosidase gene (GBA) carrier status on motor impairment in a large cohort of patients with incident Parkinson disease (PD). METHODS: Three European population-based studies followed 528 patients with PD from diagnosis. A total of 440 with genomic DNA from baseline were assessed for GBA variants. We evaluated motor and functional impairment annually using the Unified Parkinson's Disease Rating Scale (UPDRS) motor and activities of daily living (ADL) sections. Differential effects of classes of GBA variants on disease progression were evaluated using mixed random and fixed effects models. RESULTS: A total of 387 patients with idiopathic disease (age at baseline 70.3 ± 9.5 years; 60.2% male) and 53 GBA carriers (age at baseline 66.8 ± 10.1 years; 64.2% male) were included. The motor profile of the groups was clinically indistinguishable at diagnosis. GBA carriers showed faster annual increase in UPDRS scores measuring ADL (1.5 point per year, 95% confidence interval [CI] 1.1-2.0) and motor symptoms (2.2 points per year, 95% CI 1.3-3.1) compared to noncarriers (ADL, 1.0 point per year, 95% CI 0.9-1.1, p = 0.003; motor, 1.3 point per year, 95% CI 1.1-1.6, p = 0.007). Simulations of clinical trial designs showed that recruiting only GBA carriers can reduce trial size by up to 65% compared to a trial recruiting all patients with PD. CONCLUSION: GBA variants are linked to a more aggressive motor disease course over 7 years from diagnosis in patients with PD. A better understanding of PD progression in genetic subpopulations may improve disease management and has direct implications for improving the design of clinical trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Maple-Grødem J, Dalen I, Tysnes OB, et al. Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease. Neurology. 2020. PMID: 33443131. doi:10.1212/WNL.0000000000011411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。